ArticleJournal of hematology & oncology2018
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma.
Article in Journal of hematology & oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma.Journal of hematology & oncology · 2020Pooled it
- Bispecific ANXA2/CD147 CAR-T cell therapy for osteosarcoma.Oncogene · 2026Article
- Autologous stem cell transplantation in POEMS syndrome: Multicenter real-world treatment patterns and outcomes.Bone marrow transplantation · 2026Article
- POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2026Review
- BCMA CAR T-cell therapy in a patient with heavily pretreated relapsed/refractory POEMS Syndrome: a case report.Annals of hematology · 2026Article
- Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT.Annals of hematology · 2026Article
- Teclistamab for heavily pretreated relapsed/refractory POEMS syndrome.Haematologica · 2026Article
- From myeloma to POEMS: extending the potential of T-cell redirecting therapies.Haematologica · 2026Article
- Pathways of Resistance: Modern Multiple Myeloma Therapies and Overcoming Reliance on Genomic Integrity.International journal of molecular sciences · 2026Review
- POEMS syndrome: diagnosis, treatments, and outcomes.Hematology. American Society of Hematology. Education Program · 2025Article
- Cilta-cel CAR T cells as an effective and well tolerated treatment for POEMS: a case study.Haematologica · 2025Article
- [Chinese expert consensus on the diagnosis and treatment of POEMS syndrome (2025)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Article
- The Unprecedented Success of Chimeric Antigen Receptor T-Cell Therapy in the Treatment of Hematological Malignancies.Cureus · 2024Review
- Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients.Therapeutic advances in neurological disorders · 2024Article
- Unraveling the Neurological Complexity of Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Protein, and Skin Changes Syndrome: A Report of a Challenging Case of a Young Woman and Cutting-Edge Advancements in the Field.Diseases (Basel, Switzerland) · 2023Article
- Article
- Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.Cancer medicine · 2023Review
- The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.BMC cancer · 2023Article
- Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results.Signal transduction and targeted therapy · 2023Article
- Recent Advances in the Treatment and Supportive Care of POEMS Syndrome.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPOEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome still has no standard treatment. On the basis that both POEMS syndrome and myeloma have an underlying plasma cell dyscrasia, anti-myeloma therapy can be expected to be useful for POEMS syndrome. Chimeric antigen receptor T (CAR-T) cells targeting B cell maturation antigen (BCMA) has been used in the treatment of relapsed and refractory multiple myeloma (RRMM). No POEMS syndrome cases treated with anti-BCMA CAR-T cells have been reported. CASE PRESENTATION: Here, we, for the first time, report a POEMS syndrome case treated with anti-BCMA CAR-T cells. A 49-year-old female with incapacitating POEMS syndrome that progressed on lenalidomide treatment was enrolled in a phase I study involving anti-BCMA CAR-T cells (ChiCTR-OPC-16009113). Another patient with RRMM who had undergone six prior lines treatments was also enrolled in the study. They received infusions of anti-BCMA CAR-T cells. Both patients achieved a stringent complete response. Complete remission persisted in the patient with POEMS syndrome and lasted for 7.6 months before a relapse in RRMM patient. Both patients had toxicity consistent with the grade 1 cytokine release syndrome.
conclusionsThis is the first report of treatment by anti-BCMA CAR-T cells in POEMS syndrome. Our findings demonstrate the anti-BCMA CAR-T cell treatment may be a feasible therapeutic option for patients with POEMS syndrome and RRMM who do not respond well to traditional therapies.
trial registrationChiCTR-OPC, ChiCTR-OPC-16009113 . Registered 29 August 2016.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.